In addition to the aforementioned targetable alterations (BRAF V600E, RET fusions, as well as emerging HER2 mutations and KRAS G12C), multiple other predictive molecular targets exist in NSCLC. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.